Taren Grom, Editor
NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Biotech Pool Dr. Michelle BERREY Chimerix Appoints CMO Chimerix, a biotechnology company developing orally available antiviral therapeutics, has named Michelle Berrey, M.D., chief medical officer. Before joining Chimerix, Dr. Berrey was chief medical officer at Pharmasset. Lindsay ROCCO Dendreon Appoints Lead for Corporate Communications Dendreon, a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization, and manufacturing of novel therapeutics, has appointed Lindsay Rocco as executive VP, corporate communications, and member of the executive committee. In this role, Ms. Rocco is responsible for all communications functions of the company. Most recently, she was senior VP and a member of the leadership team at Rx Mosaic Health, a specialty healthcare public relations agency within the Omnicom Group. CRO Pool Cedric BURG James GUNTER Chiltern Bolsters Executive Team Chiltern International, a global contract research organization, has named Cedric Burg, Ph.D., as VP, global clinical development, Americas, and James Gunter as director of dedicated biometrics services. Dr. Burg has more than 17 years experience in the clinical research field and has a international profile having held global senior roles within both a CRO environment and pharma. He holds a master’s degree in life and health sciences from the Université de Rennes I, and a doctorate in Molecular and Cellular Biology from the Université de Nantes. Mr. Gunter brings 16 years in life-sciences experience, including 12 years in operational and management roles in the CRO industry. Sal CHIOVARI INC names Chief Information Officer INC Research, a therapeutically focused global clinical research organization, has appointed Sal Chiovari as its new chief information officer (CIO). Mr. Chiovari joins INC Research from Smith & Nephew. Jonathan FISHBEIN RPS Names Chief Medical Officer ReSearch Pharmaceutical Services (RPS), a next generation CRO that provides comprehensive global Phase I-IV clinical development solutions, has named Jonathan M. Fishbein, M.D., executive VP and chief medical officer. In this role, he is responsible for providing leadership and strategic direction to the medical, safety, and medical writing departments. Dr. Fishbein recently served as a VP in several medical and scientific capacities at ICON. Association Pool Dr. Robert DARNELL NYGC?Appoints President The New York Genome Center (NYGC) has appointed Robert Darnell, M.D., Ph.D., one of the world’s leading experts in the emerging area of RNA genomics, as its president and scientific director. In this role, Dr. Darnell will leverage his 22 years of experience in molecular neuro-oncology and leadership in RNA genomics, spanning multiple diseases and therapeutic areas. Dr. Darnell will direct all aspects of the NYGC, including its scientific and research activities, and the recruitment and development of a world-class scientific team in genomic research and medicine. Dr. Darnell, who previously advised the NYGC as a member of its founding board and executive committee, also joins the NYGC board of directors. Agency Pool Kimberly CLOTMAN Roska Healthcare Makes Executive Moves Roska Healthcare Advertising has promoted Kimberly Clotman from senior VP to executive VP, director of client services. In this newly created position, she is responsible for working across accounts to share best practices, provide strategic guidance and cultivate new and existing client relationships. Ms. Clotman was made a member of Roska Healthcare’s executive committee contributing to the overall direction and growth of the agency. Chris MYCEK Cadient Group Focuses on Commercial Innovation Cadient Group has hired Chris Mycek to a newly created role of chief customer officer. Mr. Mycek, who has more than 20 years of marketing strategy experience, will oversee Cadient Group’s customer development process. Most recently, he served as executive VP at Influence Interactive, a full-service digital agency. Susan WINGERON SciStrategy Names New VP The healthcare communications company SciStrategy Communications, a subsidiary of Meniscus Ltd., has named Susan Wingeron, as VP, strategic growth and development. In this key role, Ms Wingeron supports the company’s management in continuing to develop new opportunities growing from unprecedented advances in science and technology, and changes in the healthcare arena. Service Pool Raymond HILL inVentiv Health Strengthens Clinical Leadership Team inVentiv Health, which offers clinical, commercial, and consulting services to the healthcare industry, announced organizational changes within its clinical group. Raymond Hill has joined the company as executive VP of clinical; he is responsible for leading the company’s clinical business segment, which includes early-stage, Phase II-IV, and strategic resourcing. Previously, Mr. Hill was CEO at Pharmaceutical Product Development. Peyton HOWELL AmerisourceBergen Promotes Executive Leadership Peyton Howell has been promoted to senior VP of AmerisourceBergen Corp. and president, global sourcing and manufacturer relations. Ms. Howell was most recently senior VP, business development, AmerisourceBergen, and president of AmerisourceBergen Consulting Services. She is responsible for directing the relationships with the portfolio teams from pharma manufacturers. use your QR?CODE?READER or go to bit.ly/PV0213-TalentPool Pharma Pool R. Scott SHIVELY Zogenix Appoints New Chief Commercial Officer Zogenix, a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, has appointed R. Scott Shively to serve as executive VP and chief commercial officer. Mr. Shively previously served as VP, global commercial disease area lead for pain for Pfizer. Mr. Shively is responsible for all of Zogenix’s commercial strategies and operations, including the currently marketed product, Sumavel DosePro, and the anticipated launch of Zohydro ER, which is pending FDA approval. Biotech Pool Dr. Jeff JONAS Shire Regenerative Medicine Names President Shire has appointed Jeff Jonas, M.D., as president of its Regenerative Medicine business. After a varied career in research and development, commercial and entrepreneurial business roles, Dr. Jonas joined Shire in July 2008 as leader of the Specialty Pharmaceuticals R&D team. Charles MORRIS ImmunoGen Appoints Chief Development Officer ImmunoGen, a biotechnology company that develops anticancer therapeutics using its TAP technology and antibody expertise, has appointed Charles Morris as executive VP and chief development officer. Dr. Morris is responsible for leading all aspects of product development, including regulatory. Before joining ImmunoGen, he was the executive VP and chief medical officer at Allos Therapeutics. Biopharma Pool Dr. Victor KNOPOV Regulus Appoints VP, Pharmaceutical Development Regulus Therapeutics, a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, has appointed Victor Knopov, Ph.D., to its executive management team as VP, pharmaceutical development. Dr. Knopov joined Regulus from Nitto Denko Technical, where he served as director, chemistry manufacturing control since 2010. Dr. Joseph Laudano Alliqua Appoints VP of Medical Affairs Alliqua, an advanced biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies, has appointed Joseph Laudano, Pharm.D., to the newly created position of VP, medical affairs, to support the market expansion of its SilverSeal products as well as other future clinical developments. Thomas MITRO Omeros Appoints VP, Sales and Marketing Omeros, a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed Thomas Mitro as VP, sales and marketing. Mr. Mitro has more than 30 years of experience in the pharmaceutical industry, spanning sales and marketing as well as business development. Before joining Omeros, Mr. Mitro served from 2002 until 2012 as VP president, sales and marketing, at ISTA Pharmaceuticals. Specialty Pool Jonathan Berlent Tris Pharma Appoints VP of Business Development Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, has appointed Jonathan Berlent as VP, business development. He will lead Tris’ product and technology partnering, and collaborate with branded pharmaceutical companies on their life-cycle management opportunities. Most recently, he was president of Granules USA, where he led its North American operations. Emerging Pool Dr. Julie HAMBLETON Five Prime Therapeutics Adds Senior VP and CMO Five Prime Therapeutics, a clinical-stage company discovering and developing innovative antibody and protein therapeutics, has hired Julie Hambleton, M.D., as senior VP and chief medical officer, bringing more than 25 years of clinical, academic, and drug development experience to the role. Before joining FivePrime, Dr. Hambleton served as VP, clinical development, at Clovis Oncology. Dr. Joseph PATTI Russell PLUMB Biota Pharmaceuticals Appoints New Executive Officers Biota Pharmaceuticals has appointed Joseph Patti, Ph.D., executive VP, corporate development and strategy, and Russell Plumb as its CEO. Mr. Plumb previously served as president, CEO, and chief financial officer of Inhibitex. Dr. Patti was a co-founder of Inhibitex, and served as chief scientific officer and senior VP of research and development. Diagnostics Pool Mark Myslinski Saladax Biomedical Names Chief Commercial Officer Saladax Biomedical, a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine, has appointed Mark Myslinski as senior VP and chief commercial officer. He was recently president and CEO of RedPath Integrated Pathology. CRO Pool Dr. Susan STANSFIELD inVentiv Health Bolsters Clinical Operations PharmaNet/i3, inVentiv Health’s clinical segment, has named Susan Stansfield, Ph.D., executive VP of clinical operations for Phase II-IV development in Europe, Middle East, and Africa (EMEA), Asia-Pacific, and Latin America. Dr. Stansfield received her B.Sc. in physiology and biochemistry from Nottingham University and her Ph.D. in neuropharmacology from Reading University. Diane WONG ProTrials Continues Growth Expansion ProTrials Research has added industry veteran Diane Wong to its senior staff as director of quality assurance. Most recently, Ms. Wong was the associate director of clinical quality assurance for South San Francisco, Calif.’s Janssen Alzheimer Immunotherapy Research & Development. Ms. Wong joins ProTrials with more than 15 years of industry experience in quality and regulatory compliance. Service Pool Dr. Dalvir GILL TransCelerate BioPharma Appoints CEO TransCelerate BioPharma has appointed Dalvir Gill, Ph.D., CEO. Dr. Gill is leading the independent non-profit entity, which was formed by 10 healthcare and pharmaceutical companies in September 2012 to improve the quality of clinical studies and bring new medicines to patients faster by facilitating the collaboration required to solve common challenges encountered during the clinical trial process. Most recently, Dr. Gill was the president of Phase II-IV drug development at PharmaNet-i3. Consulting POOL Michael SWANICK PwC Appoints Global Pharmaceutical and Life Sciences Industry Leader Michael Swanick has been appointed as global pharmaceutical and life-sciences industry leader at PwC. As the global practice leader, he is responsible for the strategy and direction of the firm’s multinational pharmaceutical, medical device, and life-sciences practice. A 28-year veteran of PwC, Mr. Swanick most recently held the position of PwC’s U.S. Pharmaceutical and Life Sciences Leader and Global Tax Leader for the practice. He will continue to serve in this capacity, while taking on additional global responsibilities for the firm. Agency Pool Rob PEROTA Centron Welcomes Industry Leader Rob Perota joins Centron as executive creative director, and part of its senior management team. Mr. Perota’s career spans almost 20 years in both healthcare and consumer advertising.